Key Drivers
- Margin Compression
- Rising Leverage
- Cash Flow
AIAI Summary
Artivion's FDA-backed AMDS expansion and Endospan acquisition can create a stronger aortic-care growth platform, but the investment case now hinges on proving that revenue growth converts into sustained free cash flow and margin recovery before elevated debt constrains flexibility.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Rising Leverage
- •Cash Flow
AORT's strong liquidity and gross margins are being undermined by sharp quarterly losses, negative cash flow, rising leverage, and an expensive valuation, warranting caution pending earnings recovery.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Fresh look-back low
- •Oversold momentum
AORT fell 16.5% over the last month to a fresh $23.35 low; despite deeply oversold RSI (~21), downside risk remains elevated unless it reclaims $24.97–$25.38.
Accelerated decline from roughly $28 in late
Sentiment & News
Similar Companies in Healthcare
Other companies in the same sector with AI ratings